Personalized follow-up after limited surgery or radiation for colon cancer
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests the best way to choose and then follow treatment when colorectal cancer has spread only to a small number of spots. You may be eligible if your doctors can remove or precisely treat the spots and there’s no sign of additional spread on scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have colorectal cancer that has spread to a small number of sites (oligometastatic)
- You will have a “local” treatment to the spots (such as surgery, radiofrequency ablation, or stereotactic body radiation) and not CRS/HIPEC
- Your scans (CT chest/abdomen/pelvis) show no other distant metastases right before starting study treatment
- You must be well enough for stronger chemotherapy (performance status 0–2) and your doctor thinks you can receive standard “triple” chemo after the local treatment
- Blood tests must be strong enough for chemo (bone marrow, liver, and kidney function meeting the study limits)
- You must not have significant nerve side effects (neuropathy worse than mild) and must not be allergic/intolerant to key chemo drugs like 5-FU, oxaliplatin, irinotecan, leucovorin, or capecitabine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether an added “maintenance” treatment after liver surgery can help prevent colorectal cancer from coming back. It is only for people whose blood test (ctDNA) still shows signs of cancer after their operation.
This Phase 1 study uses a blood test called ctDNA to decide whether and how to adjust treatment in people with colon cancer who still have a small amount of disease left after surgery. If your blood test remains positive, the trial aims to reduce recurrence risk by guiding treatment changes.
This Phase 1/2 trial tests LYL273, a new targeted treatment, for people with metastatic colorectal (colon) cancer that has returned or not responded to standard chemo. It’s designed to see how well the drug can control the cancer and what side effects it causes.
This trial checks whether giving chemotherapy after surgery only for people whose blood test (ctDNA) shows no remaining cancer can help prevent the cancer from coming back. It is for people with colon cancer that has spread to the liver who had the tumor fully removed.
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
This trial studies how targeted radiation (SBRT) affects cancer biology and immune cells in people with colon cancer that has spread only to a small number of lung nodules. Your tumor tissue will be analyzed to see what changes after treatment.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.